BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £174.3m
Enterprise Value £112.7m
Revenue £12.6m
Position in Universe th / 1831

BRIEF-Transgene And BioInvent Enrol First Patient In Phase I/IIa Of Oncolytic Virus BT-001 Trial

Mon 1st March, 2021 7:11am
March 1 (Reuters) - BIOINVENT INTERNATIONAL AB  BINV.ST :
    * TRANSGENE AND BIOINVENT HAVE ENROLLED FIRST PATIENT IN
PHASE
I/IIA TRIAL OF NOVEL ONCOLYTIC VIRUS BT-001 IN SOLID TUMORS

Source text for Eikon:  ID:nBwb1RCm7a 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.